此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Evaluation of Fisetin to Reduce Systemic Senescence

2026年11月2日 更新者:Steadman Philippon Research Institute

Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study

This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.

研究概览

地位

完全的

条件

干预/治疗

详细说明

This is a prospective, randomized clinical trial designed to examine the effect of two different Fisetin dosing schedules on peripheral blood cells and biomarkers related to aging as well as the occurrence of side effects. The purpose of this study is to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood. 96 healthy volunteers will be randomized into one of two arms (1:1). Group 1 - n= 48: Fisetin Daily Dosing; Group 2 - n=48: Fisetin Bolus Dosing.

研究类型

介入性

注册 (实际的)

82

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Colorado
      • Vail、Colorado、美国、81657
        • Steadman Philippon Research Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

55年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults ≥55 years of age;
  • Capacity to personally give informed consent (consent via legally authorized representative will not be accepted);
  • Willing to comply with all study procedures and assessments.

Exclusion Criteria:

  • Within 2 years of signing informed consent history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active malignancy of any type or history of a malignancy (with the exception of Subjects with a history of treated basal or squamous cell carcinoma);

  • Females who are nursing a child, are pregnant, or are planning to become pregnant during drug dosing;

  • Males who do not wish to abstain from sex with women of childbearing potential without use of contraceptive protection by either party during drug dosing;

  • Any significant illness within the last 30 days requiring clinical care, and/or any medications, medical condition, including findings in medical history or in the baseline assessments that, in the opinion of the Principal Clinical Investigator or the screening clinician, constitutes a risk or contraindication for participation in the study or that could interfere with the study conduct, endpoint evaluation, or prevent the subject from fully participating in all aspects of the study;

  • Allergy to any active or inactive ingredient of Fisetin, and/or taking medication with known Fisetin interaction;

  • Subjects with any of the following drug/medication statuses:

    1. Taking medications that affect insulin activity, including Metformin or Acarbose, within one week of signing informed consent;
    2. Currently taking Warfarin or related anticoagulants;
    3. Currently taking Lithium;
    4. Senolytic agents taken within the past 3 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax;
    5. Taking drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, and other chemotherapy drugs;
    6. Taking the following drugs if they cannot be held (per the Principal Investigator) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan;
    7. Taking a glucocorticoid within 1 month of signing informed consent;
    8. Currently taking phenytoin or nateglinide;
  • PHQ-9 - Patient Health Questionnaire - total score exceeds 9;

  • Inability to tolerate oral medication;

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Fisetin (daily dosing)

A single Fisetin 100mg capsule will be taken daily for 60 days.

Oral Fisetin 100mg capsule

其他名称:
  • 3,3',4',7-四羟基黄酮
  • 诺乌司汀
  • 7,3',4'-flavon-3-ol
实验性的:Fisetin (bolus dosing)

Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. This cycle of 2 dosing days followed by 28 days off will repeat for a total of 2 cycles, or 4 dosing days total. Dosing days will occur on days 1&2, and 31&32.

Oral Fisetin 100mg capsule, dosed at 20 mg/kg

其他名称:
  • 3,3',4',7-四羟基黄酮
  • 诺乌司汀
  • 7,3',4'-flavon-3-ol

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
大体时间:Baseline, Visit 4 (45 days)

Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels.

Baseline, Visit 4 (45 days)

次要结果测量

结果测量
措施说明
大体时间
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
大体时间:Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)

Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels.

Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
Change from baseline in senescence-related serum biomarkers
大体时间:Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

Concentrations of proteins related to senescence will be analyzed using multiplex immunoassays and ELISA from serum/plasma.

Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
Number of participants experiencing one or more treatment-emergent adverse events
大体时间:From date of study drug dosing until the end of the study, an average of 2 months

Number of participants experiencing one or more treatment-emergent adverse events

From date of study drug dosing until the end of the study, an average of 2 months
Perturbations in senescent PBMC values
大体时间:Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels.

Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
Perturbations in senescent serum/plasma biomarkers values
大体时间:Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

The variability over visits of serum/plasma concentrations of proteins related to senescence will be assessed using multiplex immunoassay and ELISA.

Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Johnny Huard, PhD、Steadman Philippon Research Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年5月24日

初级完成 (实际的)

2024年1月30日

研究完成 (实际的)

2024年1月30日

研究注册日期

首次提交

2026年10月21日

首先提交符合 QC 标准的

2026年11月2日

首次发布 (实际的)

2026年11月5日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 2022-154

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.